S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act
S. 2210, Better Care Better Jobs Act;
H.R. 5376, Build Back Better Act
Prescription drug pricing issues.
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Duration: February 9, 2018
to
February 1, 2022
General Issues: Health Issues
Spending: about $320,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, White House Office, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Ginger Loper Special Assistant to the President for Legislative Affairs(2002-2005)
Special Assistant to the President (2002-2005)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2022
Loper Consulting LLC terminated an engagement in which they represented Patients for Affordable Drugs NOW, Inc. on May 10, 2022.
Original Filing: 301374843.xml
4th Quarter, 2021
In Q4, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Jan. 18, 2022.
Original Filing: 301324761.xml
Lobbying Issues
S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act
S. 2210, Better Care Better Jobs Act;
H.R. 5376, Build Back Better Act
Prescription drug pricing issues.
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Nov. 1, 2021.
Original Filing: 301316699.xml
Lobbying Issues
S. 2210, Better Care Better Jobs Act;
H.R. 5376, Build Back Better Act
Prescription drug pricing issues.
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on July 19, 2021.
Original Filing: 301279793.xml
Lobbying Issues
Prescription drug pricing issues.
Continued monitoring of the implementation of Families First Coronavirus Response Act (PL 116-127);
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on May 10, 2021.
Original Filing: 301270798.xml
Lobbying Issues
Continued monitoring of implementation of Families First Coronavirus Response Act (PL 116-127);
Issues of prescription drug pricing in Medicare and Medicaid.
Rebate rule.
S.1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019.
Prescription drug pricing issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Jan. 27, 2021.
Original Filing: 301247009.xml
Lobbying Issues
Issues related to drug pricing; issues related to the MFN and drug rebate rules
H.R. 3 - The Lower Drug Costs Now Act
S. 1895 - Lower Health Care Costs Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Nov. 6, 2020.
Original Filing: 301226202.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 3 - The Lower Drug Costs Now Act
H.R. 965/ S. 340, CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on July 30, 2020.
Original Filing: 301204206.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 3 - The Lower Drug Costs Now Act
H.R. 965/ S. 340, CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on June 10, 2020.
Original Filing: 301184358.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 3 - The Lower Drug Costs Now Act
H.R. 965/ S. 340, CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Feb. 19, 2020.
Original Filing: 301141953.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 3 - The Lower Drug Costs Now Act
H.R. 965/ S. 340, CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Nov. 21, 2019.
Original Filing: 301091586.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 3 - The Lower Drug Costs Now Act
H.R. 965/ S. 340, CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Sept. 4, 2019.
Original Filing: 301061827.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 965/ S. 340, CREATES Act of 2019
S. 1895 - Lower Health Care Costs Act
S. 1416 - Affordable Prescriptions for Patients Act
S. 440 - Preserving Access to Cost Effective Drugs Act
S. 1391 & H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 1520 - Purple Book Continuity Act
H.R. 1503 - Orange Book Continuity Act
S. 659 - Biologic Patent Transparency Act
S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on May 13, 2019.
Original Filing: 301040823.xml
Lobbying Issues
Issues related to drug pricing; issues related to the IPI CMMI demonstration; monitored issues related to the RFI, the Blueprint to Lower Drug Prices and Reduce Out of Pocket Costs.
H.R. 965/ S. 340, CREATES Act of 2019
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Feb. 4, 2019.
Original Filing: 301019742.xml
Lobbying Issues
S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act)
American Patients First (Drug Pricing Blueprint)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Nov. 28, 2018.
Original Filing: 301000905.xml
Lobbying Issues
S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on Aug. 21, 2018.
Original Filing: 300981057.xml
Lobbying Issues
S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).
H.R. 2051 - Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act of 2017).
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Loper Consulting LLC lobbied for Patients for Affordable Drugs NOW, Inc. , earning $20,000. The report was filed on April 26, 2018.
Original Filing: 300959227.xml
Lobbying Issues
H.R. 1892 - Bipartisan Budget Act of 2018, Omnibus.
S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).
H.R. 2051 - Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act of 2017).
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...